OCT461201

OCT461201 is a selective cannabinoid receptor type 2 (CB2) agonist developed as a potential treatment for chemotherapy-induced peripheral neuropathy (CIPN) and visceral pain, including irritable bowel syndrome (IBS). The drug acts by selectively activating the CB2 receptor, which is believed to modulate pain and inflammation without the psychoactive effects associated with cannabinoid receptor type 1 activation. OCT461201 has completed a Phase I clinical trial in healthy volunteers, demonstrating no safety or tolerability concerns at any dose tested. The compound was originally licensed from AskAt by Oxford Cannabinoid Technologies, which leads its development. Manufacturing for clinical trials has involved Benuvia Manufacturing Inc., and Simbec Research Limited conducted the Phase I study.